文献速递心脑血管急症重症综合管理与镇静镇痛

脑出血后单片低剂量三联降压药治疗

Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage.
PubMed 文献 · N Engl J Med · 2026-01-01
一句话结论脑出血患者基线收缩压130-160 mmHg,在标准治疗基础上加用替米沙坦20 mg/氨氯地平2.5 mg/吲达帕胺1.25 mg单片复方,复发性卒中风险低于安慰剂(HR 0.61)。

这项跨国双盲随机安慰剂对照试验纳入有脑出血病史、基线收缩压130-160 mmHg且临床稳定的患者,经2周活性导入期(每日一次替米沙坦20 mg、氨氯地平2.5 mg、吲达帕胺1.25 mg单片复方)后随机分为继续三联片组或安慰剂组。共1670例患者随机,三联片组833例、安慰剂组837例,平均年龄58岁,中位随访2.5年。三联片组复发性卒中38例(4.6%)低于安慰剂组62例(7.4%)(HR 0.61;95%CI 0.41-0.92;P=0.02),随访期间平均收缩压分别为127 mmHg和138 mmHg。三联片组主要心血管事件发生率6.6%低于安慰剂组9.8%(P=0.04),严重不良事件发生率23.2% vs 26.0%,因不良事件提前停药13.6% vs 6.0%,最常见停药原因为血清肌酐升高≥20%。

要点

  • 脑出血后基线收缩压130-160 mmHg且临床稳定的患者,在标准治疗基础上加用三联单片复方(替米沙坦20 mg、氨氯地平2.5 mg、吲达帕胺1.25 mg,每日一次)较安慰剂降低复发性卒中风险(HR 0.61;95%CI 0.41-0.92;P=0.02)。
  • 三联片组随访期间平均收缩压127 mmHg,安慰剂组138 mmHg,两组相差11 mmHg。
  • 主要心血管事件三联片组6.6% vs 安慰剂组9.8%(P=0.04)。
  • 因不良事件提前停药三联片组13.6% vs 安慰剂组6.0%,最常见停药原因为血清肌酐升高≥20%。
  • 严重不良事件发生率三联片组23.2% vs 安慰剂组26.0%。

适用人群与场景

  • 有脑出血病史、基线收缩压130-160 mmHg且临床稳定的患者;跨国、双盲、随机、安慰剂对照试验人群。

诊断标准与关键阈值

  • 入组标准:有脑出血病史,基线收缩压130-160 mmHg,临床稳定。

处置流程与药物剂量

  • 所有患者先接受2周活性导入期,每日一次口服单片复方(替米沙坦20 mg、氨氯地平2.5 mg、吲达帕胺1.25 mg;三联片)。
  • 导入期后随机继续接受三联片或匹配安慰剂,在标准降压治疗基础上加用。

研究设计与关键结果

  • 研究类型:跨国、双盲、随机、安慰剂对照试验;样本量1670例(三联片组833例,安慰剂组837例);平均年龄58岁;中位随访2.5年。
  • 主要终点(首次复发性卒中):三联片组38例(4.6%)vs 安慰剂组62例(7.4%),HR 0.61(95%CI 0.41-0.92),P=0.02。
  • 随访期间平均收缩压:三联片组127 mmHg vs 安慰剂组138 mmHg。
  • 主要心血管事件:三联片组6.6% vs 安慰剂组9.8%,P=0.04。
  • 严重不良事件:三联片组23.2% vs 安慰剂组26.0%。
  • 因不良事件提前停药:三联片组13.6% vs 安慰剂组6.0%;最常见停药原因为血清肌酐升高≥20%。

证据类型、等级与局限

  • 证据类型:跨国、双盲、随机、安慰剂对照试验(TRIDENT,NCT02699645)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对有脑出血病史、基线收缩压130-160 mmHg且临床稳定的患者,在标准治疗基础上加用替米沙坦20 mg、氨氯地平2.5 mg、吲达帕胺1.25 mg单片复方每日一次,可降低复发性卒中和主要心血管事件风险。
  • 使用中需监测血清肌酐,因血清肌酐升高≥20%是导致提前停药的最常见不良事件。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Blood-pressure reduction is the only proven treatment to prevent stroke. Whether a single pill that combines three antihypertensive drugs at low doses, in addition to standard antihypertensive treatment, can lower blood pressure more than standard care alone and reduce the risk of recurrent stroke after intracerebral hemorrhage is uncertain.

METHODS: We conducted a multinational, double-blind, randomized, placebo-controlled trial involving patients with a history of intracerebral hemorrhage. Patients were eligible for the trial if they had a systolic blood pressure of 130 to 160 mm Hg at baseline and were in clinically stable condition. After a 2-week active run-in phase during which all the patients received a once-daily pill containing three antihypertensive agents at low doses (telmisartan at 20 mg, amlodipine at 2.5 mg, and indapamide at 1.25 mg; the triple pill), the patients were randomly assigned to continue receiving the triple pill or to receive matching placebo. The primary outcome was the first recurrent stroke. Secondary outcomes included blood-pressure control, major cardiovascular events, death from cardiovascular causes, and safety.

RESULTS: Of 1670 patients who underwent randomization, 833 were assigned to receive the triple pill and 837 to receive placebo. The mean age of the patients was 58 years. At a median follow-up of 2.5 years, recurrent stroke had occurred in 38 patients (4.6%) in the triple-pill group and 62 (7.4%) in the placebo group (hazard ratio, 0.61; 95% confidence interval [CI], 0.41 to 0.92; P = 0.02). The mean systolic blood pressure during follow-up was 127 mm Hg and 138 mm Hg, respectively. The incidence of major cardiovascular events was lower with the triple pill than with placebo (6.6% vs. 9.8%; P = 0.04). Serious adverse events occurred in 23.2% of the patients in the triple-pill group and 26.0% of those in the placebo group. Early discontinuation of the trial regimen due to an adverse event occurred in 13.6% and 6.0%, respectively. The most common adverse event leading to discontinuation was an increase of 20% or more in the serum creatinine level.

CONCLUSIONS: Among patients with intracerebral hemorrhage, treatment with a combination of three low-dose antihypertensive agents in a single pill, in addition to standard care, was associated with a lower incidence of recurrent stroke and major cardiovascular events than placebo. (Funded by the National Health and Medical Research Council of Australia and the Brazilian Ministry of Health; TRIDENT ClinicalTrials.gov number, NCT02699645; Australian New Zealand Clinical Trials Registry number, ACTRN12616000327482.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Anderson CS, Chow CK, de Silva HA, et al. Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage. N Engl J Med. 2026. PMID: 42019018. doi:10.1056/NEJMoa2515043

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。